Discovery of pyrroloaminopyrazoles as novel PAK inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 10, 2012, Pages 4728-4739

  Guo, Chuangxing ^a   McAlpine, Indrawan ^a   Zhang, Junhu ^a   Knighton, Daniel D ^a   Kephart, Susan ^a   Johnson, M Catherine ^a   Li, Haitao ^a   Bouzida, Djamal ^a   Yang, Anle ^a   Dong, Liming ^a   Marakovits, Joseph ^a   Tikhe, Jayashree ^a   Richardson, Paul ^a   Guo, Lisa C ^a   Kania, Robert ^a   Edwards, Martin P ^a   Kraynov, Eugenia ^a   Christensen, James ^a   Piraino, Joseph ^a   Lee, Joseph ^a   Dagostino, Eleanor ^a   Del Carmen, Christine ^a   Deng, Ya Li ^a   Smeal, Tod ^a   Murray, Brion W ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZAMIDO N [2 (DIMETHYLAMINO) 1 PHENYLETHYL] 6,6 DIMETHYL 4,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 5(1H)CARBOXAMIDE; 5 TERT BUTYL 2 ETHYL 3 BENZAMIDO 6,6 DIMETHYLPYRROLO[3,4C]PYRAZOLE 2,5(4H,6H)DICARBOXYLATE; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; ETHYL 3 BENZAMIDO 5 (CHLOROCARBONYL) 6,6 DIMETHYL 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 3 BENZAMIDO 6,6 DIMETHYL 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 3 (2 FLUOROBENZAMIDO) 6,6 DIMETHYL 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 3 (2,4 DIFLUOROBENZAMIDO) 6,6 DIMETHYL 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 3 (4 FLUOROBENZAMIDO) 6,6 DIMETHYL 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 6,6 DIMETHYL 3 (PICOLINAMIDO) 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 6,6 DIMETHYL 3 (TETRAHYDRO 2H PYRAN 2 CARBOXAMIDO) 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 6,6 DIMETHYL 3 (TETRAHYDROFURAN 2 CARBOXAMIDO) 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; ETHYL 5 (CHLOROCARBONYL) 6,6 DIMETHYL 3 PIVALAMIDO 5,6 DIHYDROPYRROLO[3,4 C]PYRAZOLE 2(4H)CARBOXYLATE; N1,N1 DIMETHYL 2 PHENYLETHANE 1,2 DIAMINE; PROTEIN P21 ACTIVATED KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRROLOAMINOPYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; MEDICINAL PLANT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; CRYSTALLOGRAPHY, X-RAY; DOGS; HUMANS; HYDROGEN BONDING; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; P21-ACTIVATED KINASES; PERMEABILITY; PYRAZOLES; PYRROLES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861510552     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300204j     Document Type: Article

References (19)

1. Qiu, R. G.; Chen, J.; McCormick, F.; Symons, M. A role for Rho in Ras transformation Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11781
2. Zohn, I. M.; Campbell, S. L.; Khosravi-Far, R.; Rossman, K. L.; Der, C. J. Rho family proteins and Ras transformation: the RHOad less traveled gets congested Oncogene 1998, 17, 1415
3. Jaffe, A. B.; Hall, A. Rho GTPases: Biochemistry and Biology Annu. Rev. Cell Dev. Biol. 2005, 21, 247
4. Ellenbroek, S. I.; Collard, J. G. Rho GTPases: functions and association with cancer Clin. Exp. Metastasis 2007, 24, 657
5. Vega, F. M.; Ridley, A. J. Rho GTPases in cancer cell biology FEBS Lett. 2008, 582, 2093
6. Arias-Romero, L. E.; Chernoff, J. A tale of two Paks Biol. Cell 2008, 100, 97
7. Dummler, B.; Ohshiro, K.; Kumar, R.; Field, J. Pak protein kinases and their role in cancer Cancer Metastasis Rev. 2009, 28, 51
8. Eswaran, J.; Soundararajan, M.; Kumar, R.; Knapp, S. UnPAKing the class differences among p21-activated kinases Trends Biochem. Sci. 2008, 33, 394
9. Molli, P. R.; Li, D. Q.; Murray, B. W.; Rayala, S. K.; Kumar, R. PAK signaling in oncogenesis Oncogene 2009, 28, 2545
10. Birkenfeld, J.; Nalbant, P.; Yoon, S.-H.; Bokoch, G. M. Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: Is altered GEF-H1 activity a crucial determinant of disease pathogenesis? Trends Cell Biol. 2008, 18 (6) 210-219
11. Vadlamudi, R. K.; Adam, L.; Wang, R. A.; Mandal, M.; Nguyen, D.; Sahin, A.; Chernoff, J.; Hung, M. C.; Kumar, R. Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-Independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer Cells J. Biol. Chem. 2000, 275, 36238
12. Qu, J.; Cammarano, M. S.; Shi, Q.; Ha, K. C.; de Lanerolle, P.; Minden, A. Activated PAK4 Regulates Cell Adhesion and Anchorage-Independent Growth Mol. Cell. Biol. 2001, 21, 3523
13. Callow, M. G.; Clairvoyant, F.; Zhu, S.; Schryver, B.; Whyte, D. B.; Bischoff, J. R.; Jallal, B.; Smeal, T. Requirement for PAK4 in the Anchorage-Independent Growth of Human Cancer Cell Lines J. Biol. Chem. 2002, 277, 550
14. Murray, B. W.; Guo, C.; Piraino, J.; Westwick, J. K.; Zhang, C.; Lamerdin, J.; Dagostino, E.; Knighton, D.; Loi, C. M.; Zager, M.; Kraynov, E.; Popoff, I.; Christensen, J. G.; Martinez, R.; Kephart, S. E.; Marakovits, J.; Karlicek, S.; Bergqvist, S.; Smeal, T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth Proc. Natl. Acad. Sci. U.S.A. 107, 9446-9451.
15. Ong, C. C.; Jubb, A. M.; Haverty, P. M.; Zhou, W.; Tran, V.; Truong, T.; Turley, H.; O'Brien, T.; Vucic, D.; Harris, A. L.; Belvin, M.; Friedman, L. S.; Blackwood, E. M.; Koeppen, H.; Hoeflich, K. P. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 7177-7182.
16. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002 (Pubitemid 29422500)
17. All log D values cited herein are experimental data following Analiza's octanol/buffer partitioning method. Link: Analiza; Analiza, Inc.: Cleveland, OH; http://www.analiza.com/adme/adme-services.html.
18. Brasca, M. G.; Amici, R.; Fancelli, D.; Nesi, M.; Orsini, P.; Orzi, F.; Roussel, P.; Vulpetti, A.; Pevarello, P. Substituted Pyrrolo-Pyrazole Derivatives As Kinase Inhibitors. PCT Int. Appl. WO 2004056827 A2 20040708, 2004.
19. Press, B.; Di Grandi, D. Permeability for Intestinal Absorption: Caco-2 and Related Issues Curr. Drug Metab. 2008, 9, 893 and references cited therein.